FDA-cleared heart analysis software company showcased among top Midwest startups at premier venture conference.
InvestMidwest brings together approximately 300 attendees from across the country, offering entrepreneurs seeking seed through Series B funding the opportunity to engage with leading investors through on-stage presentations, structured networking, and one-on-one meetings. CardioWise participated in the conference’s MedTech track, where Coats highlighted the company’s differentiated approach to early cardiac diagnosis.
“We were proud to bring CardioWise to InvestMidwest and share our vision for transforming how heart disease is detected and diagnosed,” said Jack Coats, CEO of CardioWise. “Our platform has the potential to become the single most effective tool for patients to receive an accurate, early diagnosis and InvestMidwest was an ideal venue to connect with investors who share our passion for improving patient outcomes.”
About CardioWise
CardioWise connects cardiac CT data with innovative artificial intelligence algorithms that augment clinical decision-making within existing workflows. The company’s non-invasive cCT analysis software, SQuEEZ® (Stretch Quantifier for Endocardial Engraved Zones), produces an intuitive 3D model of the human heart using color-coded indicators to communicate heart health at a glance since the results are compared to CardioWise Normal Hearts Database.
SQuEEZ received U.S. FDA 510(k) clearance in January 2021. CardioWise has since been recognized as a Rising Star at the UCSF Health Hub Awards and was selected by GE Healthcare and Nex Cubed for the inaugural Edison Accelerator in Canada. The company’s mission is to increase diagnostic accuracy, enable more timely interventions, and help reduce the cost of cardiac healthcare globally. To learn more, visit cardiowiseinc.com